Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: Dapagliflozin in NAFLD with Primary Hypothyroidism
NCT06373523Phase 1Active, not recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Dapagliflozin Plus levothyroxine Group with Levothyroxine daily and Placebo pill (2 arms). Primary endpoint: Change in liver fat content at 28 weeks. Started Jan 2024; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06373523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373523.